Eradication of melanomas by targeted elimination of a minor subset of tumor cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 6, 2011, Pages 2474-2479

  Schmidt, Patrick ^a   Kopecky, Caroline ^a   Hombach, Andreas ^a   Zigrino, Paola ^a   Mauch, Cornelia ^a   Abken, Hinrich ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; CHIMERIC ANTIBODY; HIGH MOLECULAR WEIGHT MELANOMA ASSOCIATED ANTIGEN; MELANOMA ASSOCIATED CHONDROITIN SULFATE PROTEOGLYCAN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; BIOLOGICAL THERAPY; CANCER THERAPY; CELL SUBPOPULATION; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; ERADICATION THERAPY; FLOW CYTOMETRY; HUMAN; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TARGET CELL; TUMOR BIOPSY; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD20; CELL LINE, TRANSFORMED; HUMANS; MELANOMA; MELANOMA-SPECIFIC ANTIGENS; MICE; MICE, MUTANT STRAINS; NEOPLASM PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 79952302092     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1009069108     Document Type: Article

References (25)

1. Thompson JF, Scolyer RA, Kefford RF (2005) Cutaneous melanoma. Lancet 365:687-701. (Pubitemid 40260892)
2. Phan GQ, et al. (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:8372-8377. (Pubitemid 36842552)
3. Wheatley K, et al. (2003) Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 29:241-252. (Pubitemid 37069655)
4. Rosenberg SA, et al. (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271:907-913.
5. Dudley ME, et al. (2002) A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 25(3):243-251. (Pubitemid 34533314)
6. Morgan RA, et al. (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126-129. (Pubitemid 44547756)
7. Khammari A, et al. (2009) Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones. J Invest Dermatol 129:2835-2842.
8. Rosenberg SA, Dudley ME (2009) Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21:233-240.
9. Eshhar Z (2008) Therapeutic Antibodies, eds Chernajovsky Y, Nissim A (Springer, Berlin Heidelberg), pp 329-342.
10. Campoli MR, et al. (2004) Human high molecular weight-melanoma-associated antigen (HMW-MAA): A melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol 24:267-296. (Pubitemid 40052428)
11. Koehler H, Kofler D, Hombach A, Abken H (2007) CD28 costimulation overcomes transforming growth factor-beta-mediated repression of proliferation of redirected human CD4+ and CD8+ T cells in an antitumor cell attack. Cancer Res 67:2265-2273. (Pubitemid 46424246)
12. Quintana E, et al. (2010) Phenotypic heterogeneity among tumorigenic melanoma cells frompatients that is reversible and not hierarchically organized. Cancer Cell 18:510-523.
13. Cvetković RS, Perry CM (2006) Rituximab: A review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 66:791-820. (Pubitemid 43778729)
14. Fanale MA, Younes A (2007) Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs 67:333-350. (Pubitemid 46425549)
15. McLaughlin P, et al. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833. (Pubitemid 28363048)
16. Coiffier B, et al. (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927-1932. (Pubitemid 28446681)
17. Aklilu M, et al. (2004) Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann Oncol 15(7):1109-1114. (Pubitemid 39099116)
18. Bargou R, et al. (2008) Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321:974-977.
19. Dingli D, Michor F (2006) Successful therapy must eradicate cancer stem cells. Stem Cells 24:2603-2610. (Pubitemid 46052998)
20. Horwich A, Shipley J, Huddart R (2006) Testicular germ-cell cancer. Lancet 367:754-765. (Pubitemid 43326294)
21. Fang D, et al. (2005) A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65:9328-9337. (Pubitemid 41508000)
22. Sonoki T, et al. (2009) Establishment of a novel CD20 negative mature B-cell line, WILL2, from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximab. Int J Hematol 89:400-402.
23. Hombach A, et al. (1999) A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA. Gene Ther 6:300-304. (Pubitemid 29089929)
24. Cooper LJN, et al. (2003) T-cell clones can be rendered specific for CD19: Toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 101:1637-1644. (Pubitemid 36182545)
25. Müller T, et al. (2008) Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother 57:411-423. (Pubitemid 350295385)